Among the women diagnosed with BC, 80–90% were diagnosed with an HER-2 (human epidermal growth factor receptor 2) negative tumor, which is characterized by a downregulated expression of the HER2 gene (Slamon et al., 1987; Schettini et al., 2021). Here, ERBB2 is linked to neoplasm.